Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to 13 newly hired employees on March 31, 2026, covering an aggregate of 679,900 shares.
The options carry a $1.39 exercise price equal to the closing price on the grant date, vest over four years (25% at one year, then quarterly), and have a 10-year term under Akebia’s inducement award program in accordance with Nasdaq Listing Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – AKBA
-4.35%
-4.35%Session close to close
In the Apr 6 session, AKBA declined 4.35%, reflecting a moderate negative market reaction.
This announcement details standard Nasdaq Rule 5635(c)(4) inducement grants: 679,900 stock options f...
Analysis
This announcement details standard Nasdaq Rule 5635(c)(4) inducement grants: 679,900 stock options for 13 new employees at an exercise price of $1.39, vesting over four years with a 10-year term. It follows prior routine updates such as earlier inducement awards and the recent R&D Day notice. Investors tracking Akebia may focus more on previously disclosed revenue trends, cash of $184.8M, and pipeline milestones to assess the broader equity story.
Key Figures
New-hire options:679,900 sharesExercise price:$1.39 per shareVesting schedule:25% at 1 year; 75% quarterly+5 more
8 metrics
New-hire options679,900 sharesAggregate options granted to 13 newly hired employees on March 31, 2026
Exercise price$1.39 per shareOption exercise price, equal to closing price on March 31, 2026
Vesting schedule25% at 1 year; 75% quarterlyFour-year vesting subject to continued service
Option term10 yearsTerm of each inducement stock option grant
Current share price$1.41Price prior to publication; up 1.44% over 24 hours
52-week range$1.14–$4.0787Current price 23.68% above low, 65.43% below high
Market cap$372,352,142Equity value prior to the inducement grant announcement
Shares float251,429,553 sharesFree float from risk context
Scheduled Q4 and full‑year 2025 earnings release and conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Earnings news saw a notable positive move, while conference and administrative items (including prior inducement grants) showed flat-to-modest negative reactions.
Recent Company History
Over recent months, Akebia highlighted its kidney-focused pipeline via an April 2, 2026 virtual R&D Day announcement and participation in the Leerink Partners 2026 healthcare conference. It previously reported inducement grants on February 27, 2026, structurally similar to today’s Nasdaq Rule 5635(c)(4) options. Financially, Q4 and full‑year 2025 results showed stronger revenues and a narrowed net loss, following earlier guidance about the earnings release date. Today’s inducement awards fit into this pattern of routine corporate and compensation updates around a strengthening commercial base.
"The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
stock optionfinancial
"Each stock option has a 10-year term and is subject to the terms and conditions..."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise pricefinancial
"The options have an exercise price of $1.39 per share, which is equal to the closing price..."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"The stock options vest over four years, with 25% of the shares vesting on the first anniversary..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 13 newly-hired employees options to purchase an aggregate of 679,900 shares of Akebia’s common stock on March 31, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $1.39 per share, which is equal to the closing price of Akebia’s common stock on the grant date. The stock options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with Akebia. Each stock option has a 10-year term and is subject to the terms and conditions of Akebia’s inducement award program and a stock option agreement covering the grant.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
How many shares did Akebia (AKBA) grant in inducement options on March 31, 2026?
Akebia granted inducement options covering 679,900 shares to 13 new employees. According to Akebia, the grants were made under Nasdaq Listing Rule 5635(c)(4) to induce each hire to join the company and are subject to plan and agreement terms.
What is the exercise price and term of the AKBA inducement stock options granted March 31, 2026?
The options have an exercise price of $1.39 per share and a 10-year term. According to Akebia, $1.39 equals the closing price on the grant date and each option is governed by the inducement award program.
How do the Akebia (AKBA) inducement options vest for employees hired March 31, 2026?
Options vest over four years with 25% at the first anniversary and the remaining 75% vesting quarterly thereafter. According to Akebia, vesting is contingent on the new employee’s continued service with the company.
Do Akebia's (AKBA) March 31, 2026 inducement grants comply with Nasdaq rules?
Yes. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4), which permits inducement awards for new hires. According to Akebia, the awards follow the company’s inducement award program and option agreements.
Will the AKBA inducement options granted March 31, 2026 cause immediate dilution?
The company granted options on 679,900 shares, which may dilute existing shareholders when exercised. According to Akebia, these are inducement awards; actual dilution depends on future exercises and outstanding share count.
